Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.59 |
| ▸ | AXL | P30530 | 9/20 | 0.58 |
| ▸ | MAP1LC3B | Q9GZQ8 | 4/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.55 |
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | IL1B | P01584 | 1/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30437700 | 1.00 | CRBN (0.59) | CRBNAXLMAP1LC3BIKZF3IKZF1 | |
| SCHEMBL30189515 | 1.00 | CRBN (0.59) | CRBNAXLMAP1LC3BIKZF3IKZF1 | |
| SCHEMBL30438170 | 1.00 | CRBN (0.59) | CRBNAXLMAP1LC3BIKZF3IKZF1 | |
| SCHEMBL30437917 | 1.00 | CRBN (0.59) | CRBNAXLMAP1LC3BIKZF3IKZF1 | |
| SCHEMBL30438173 | 1.00 | CRBN (0.59) | CRBNAXLMAP1LC3BIKZF3IKZF1 | |
| SCHEMBL30262794 | 1.00 | CRBN (0.59) | CRBNAXLMAP1LC3BIKZF3IKZF1 | |
| SCHEMBL30437678 | 1.00 | CRBN (0.59) | CRBNAXLMAP1LC3BIKZF3IKZF1 | |
| SCHEMBL30438172 | 1.00 | CRBN (0.59) | CRBNAXLMAP1LC3BIKZF3IKZF1 | |
| SCHEMBL22464272 | 1.00 | CRBN (0.59) | CRBNAXLMAP1LC3BIKZF3IKZF1 | |
| SCHEMBL30438149 | 1.00 | CRBN (0.59) | CRBNAXLMAP1LC3BIKZF3IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110615779-B | Process for preparing lenalidomide derivatives | 上海科技大学 | 2023-03-24 | — | — | CN | claimed |
| EP-4734989-A2 | SYNTHESIS AND IN VITRO CHARACTERIZATION OF PROTEOLYSIS TARGETING CHIMERAS (PROTACS) FOR DEGRADATION OF DNA METHYLTRANSFERASE 1 (DNMT1) | Dana-Farber Cancer Institute, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3725771-B1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-02-04 | — | — | EP | disclosed |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-10-23 | — | — | US | disclosed |
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2025-08-19 | — | — | US | disclosed |
| US-20250144223-A1 | PROTEIN DEGRADATION COMPOUND BASED ON NAMPT TARGET PROTEIN AND APPLICATION THEREOF | GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| CN-115894506-B | Chimeric molecule and preparation method and application thereof | 四川大学 | 2025-03-18 | — | — | CN | disclosed |
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent KGaA (DE) | 2025-01-30 | — | — | US | disclosed |
| CN-119330963-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2025006902-A2 | SYNTHESIS AND IN VITRO CHARACTERIZATION OF PROTEOLYSIS TARGETING CHIMERAS (PROTACS) FOR DEGRADATION OF DNA METHYLTRANSFERASE 1 (DNMT1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20220257776-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-08-18 | — | — | US | disclosed |
| WO-2022169834-A2 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-08-11 | — | — | WO | disclosed |
| EP-4029499-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | Shanghaitech University (CN) | 2022-07-20 | — | — | EP | disclosed |
| US-20220016102-A1 | ER PROTEIN REGULATORS AND USE THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-01-20 | — | — | US | disclosed |
| CN-112592331-B | Oseltamivir PROTAC compound, preparation method thereof and application thereof in anti-influenza virus drugs | 武汉大学 | 2021-10-22 | — | — | CN | disclosed |
| WO-2021078301-A1 | PROTEIN DEGRADING AGENT AND USE THEREOF IN TREATMENT OF DISEASES | 上海科技大学 | 2021-04-29 | — | — | WO | disclosed |
| CN-112592331-A | Oseltamivir PROTAC compound, preparation method thereof and application thereof in anti-influenza virus drugs | 武汉大学 | 2021-04-02 | — | — | CN | disclosed |
| WO-2020249048-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | 上海科技大学 | 2020-12-17 | — | — | WO | disclosed |
| EP-3725771-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | Shanghaitech University (CN) | 2020-10-21 | — | — | EP | disclosed |
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | ALK, MYC, ALKBH3 | CRBN 665/4885AXL 1754/4885MAP1LC3B 4018/4885 |
| US-20220257776-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | ALK, MYC, ALKBH3 | CRBN 665/4885AXL 1754/4885MAP1LC3B 4018/4885 |
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | ADRM1, VHL, MDM2 | CRBN 6/4885AXL 359/4885MAP1LC3B 809/4885 |
| US-20220016102-A1 | ER PROTEIN REGULATORS AND USE THEREOF | ESR2, ESRRG, ESRRA | CRBN 18/4885AXL 1537/4885MAP1LC3B 968/4885 |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | CRBN 109/4885AXL 4280/4885MAP1LC3B 3008/4885 |
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, UBQLN1, TTI1 | CRBN 2656/4885AXL 3696/4885MAP1LC3B 278/4885 |
| US-20250144223-A1 | PROTEIN DEGRADATION COMPOUND BASED ON NAMPT TARGET PROTEIN AND APPLICATION THEREOF | NAMPT, NAPRT, PCMT1 | CRBN 4634/4885AXL 2160/4885MAP1LC3B 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.